As U.S. consumers are asked to shoulder more prescription drug costs, drugmakers say prices for brand-name medicines will keep rising, mainly because use of their products reduces other healthcare costs.
As U.S. consumers are asked to shoulder more prescription drug costs, drugmakers say prices for brand-name medicines will keep rising, mainly because use of their products reduces other healthcare costs.
Switzerland-based Roche Holding AG has a growth rate above the industry average due to its "high-quality" products that command "better prices, with fewer price cuts," Chief Financial Officer, Alan Hippe said, speaking at the annual JP Morgan Healthcare Conference in San Francisco earlier this week.
As long as Roche, maker of drugs like Herceptin for breast cancer, can prove that its new therapies work better than existing drugs, it can maintain pricing trends, Hippe said.
The company's leukemia drug Gazyva, priced at around $41,000 for a course of therapy, was the first to receive approval last year under a new U.S. regulatory program for "breakthrough" therapies that show promise in early testing. The Food and Drug Administration launched the pathway in response to scientific advances, especially targeted therapies designed to work for those with certain genetic mutations.
Read the full story here:http://reut.rs/1anjOpA
Source: Reuters
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen